Boston Scientific Neuromodulation Corporation Awarded $83M for neuromodulation procedural packages and ancillary items
Boston Scientific Neuromodulation Corp., Valencia, California, has been awarded a maximum $83,112,763 fixed-price with economic-price-adjustment, indefinite-delivery/indefinite-quantity contract for neuromodulation procedural packages and ancillary items. This was a sole-source acquisition using justification 10 U.S. Code 2304 (c)(1), as stated in Federal Acquisition Regulation 6.302-1. This is a one-year base contract with four one-year option periods. Location of performance is California, with an Aug. 16, 2022, ordering period end date. Using military services are Army, Navy and Air Force. Type of appropriation is fiscal 2021 through 2022 defense working capital funds. The contracting activity is the Defense Logistics Agency Troop Support, Philadelphia, Pennsylvania (SPE2DE-21-D-0008).
Boston Scientific makes medical supplies and devices used in interventional medical procedures. A leader in devices addressing heart conditions, the firm focuses on manufacturing cardiovascular and cardiac rhythm management (CRM) products. It also makes devices used for electrophysiology, endoscopy, pain management (neuromodulation), urology, and women’s health. Its roughly 13,000 diagnostic and treatment products — made in more than a dozen factories worldwide — include biopsy forceps, catheters, coronary and urethral stents, defibrillators, needles, and pacemakers. Boston Scientific markets its products in about 120 countries, but the US generates more than half of sales. (www.dnb.com)